Figure 1.

Quit rates (proportion of group achieving cotinine-verified 7-day abstinence at week 26) by actual treatment assignment and judged treatment assignment. For participants receiving buproprion, those who correctly judged bupropion were more likely to have quit than those that incorrectly judged placebo or were uncertain (29.3% vs. 14.3% vs. 21.7%, respectively). Further, among participants receiving placebo, those who incorrectly judged bupropion or correctly judged placebo were less likely to quit than those who were uncertain (16.5% vs. 11.5% vs. 23.9%).